fatal familial insomnia
MONDO:0010808
Fatal familial insomnia (FFI) is a very rare form of prion disease characterized by subacute onset of insomnia showing as a reduced overall sleep time, autonomic dysfunction, and motor disturbances.
Research intelligence
Directly mapped studies only · unique clinical trialsCurrent registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.
Medications under investigation
Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.
MONDO disease family
Recruiting studies by city
Trial status
Trial phase
Study start year
Investigated drug interventions
Fatal insomnia
Fatal insomnia is a rare, invariably fatal neurodegenerative disease and prion disease characterized by progressive and unrelenting insomnia, autonomic dysfunction, and rapid cognitive decline. The condition is classified into two distinct forms based on its underlying etiology. The vast majority of diagnoses are hereditary cases known as fatal familial insomnia (FFI), which stem directly from a dominant mutation in the PRNP gene. The remaining minority of cases occur sporadically without any underlying genetic mutation, a variant recognized clinically as sporadic fatal insomnia (sFI). The hallmark symptom of fatal insomnia is profound trouble sleeping, which typically begins as a gradual disruption of the sleep cycle but worsens relentlessly over time. Eventually, affected patients enter a permanent state of complete sleep inability clinically termed agrypnia excitata. This profound state of sustained wakefulness and sleep deprivation leads directly to other severe neurological symptoms, including speech problems, impaired motor coordination, and rapidly advancing dementia. The disease is universally fatal, typically resulting in the patient's death within a few months to a few years following the onset of symptoms, and there is currently no known disease-modifying treatment available in modern medicine.
Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.Drugs being studied
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.